US · BCTXW
BriaCell Therapeutics Corp.
- Sector
- Healthcare · Biotechnology
- Headquarters
- West Vancouver, BC V7T 2X1
- Website
- briacell.com
Price · as of 2025-07-31
—
Market cap 1.7K
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | — | — |
| Intrinsic Value(DCF) | — | — |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | |||||
| 2018 | |||||
| 2019 | |||||
| 2020 | |||||
| 2021 | |||||
| 2022 | |||||
| 2023 | |||||
| 2024 | |||||
| 2025 |
AI valuation
Our deep-learning model estimates BriaCell Therapeutics Corp.'s (BCTXW) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- —
- Current price
- —
- AI upside
- —
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
—
— upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| BCTXW | BriaCell Therapeutics Cor… | $0.00 | 1.7K | — | — | — | — | — | — | — | — | — | — | 0.00% | — | — | -237.76% | -2090.29% | -192.98% | 0.00 | -735.71 | 5.01 | 4.69 | 0.29 | 191519.00% | — | 1459.00% | — | -7.08 | -1560.53% | — | 0.00% | — | — | — | — | — |
| CELU | Celularity Inc. | $1.23 | 29.59M | +3,881% | -60% | — | — | -0.47 | 3.05 | 0.50 | -2.17 | — | -3.47 | 72.36% | -70.75% | -106.77% | -232.51% | -41.90% | -41.86% | 7.79 | -6.12 | 0.38 | 0.27 | -1.56 | -7600.00% | 13811.00% | -8464.00% | -24.37% | -0.12 | -7.17% | 0.00% | 0.00% | 0.00% | -2.48 | -14.48 | 1.75 | -10.21 |
| KTTA | Pasithea Therapeutics Cor… | $0.88 | 6.56M | — | — | — | — | -0.09 | 0.09 | — | 0.41 | — | 0.21 | 0.00% | — | — | -72.83% | -189.89% | -65.93% | 0.00 | — | 6.58 | 6.18 | 0.51 | -246.00% | — | 345.00% | -1067.47% | -12.43 | -185.53% | 0.00% | 0.00% | 0.00% | 0.39 | 0.40 | — | -6.17 |
| LIXT | Lixte Biotechnology Holdi… | $2.89 | 13.15M | — | — | — | — | -0.75 | 3.26 | — | -0.47 | — | 3.26 | 0.00% | — | — | -148.73% | 1699.47% | -131.50% | 0.00 | — | 3.26 | 3.26 | 0.29 | -4023.00% | — | -2629.00% | -117.26% | -9.94 | 1505.28% | 0.00% | 0.00% | 0.00% | -0.46 | -0.52 | — | -68.09 |
| NUWE | Nuwellis, Inc. | $1.51 | 1.36M | +27,595% | +4,040% | — | — | -6.49 | 11.10 | 8.29 | -6.45 | — | 11.10 | 66.66% | -125.72% | -127.75% | -229.24% | -1021.66% | -113.73% | 0.08 | -1.96 | 3.46 | 2.67 | 0.43 | -9778.00% | -140.00% | -4693.00% | -13.32% | -3.75 | -897.35% | 0.00% | 0.00% | 2.08% | -6.18 | -7.04 | 7.77 | -31.39 |
| SABS | SAB Biotherapeutics, Inc. | $4.10 | 39.19M | +213% | -84% | — | +2,692% | -0.44 | 0.58 | 11.35 | 0.04 | — | 0.58 | -262.41% | -3244.87% | -2579.03% | -81.92% | -519.55% | -53.23% | 0.18 | -134.77 | 2.98 | 2.61 | 0.15 | -5183.00% | -4094.00% | 3679.00% | -230.79% | -4.30 | -419.29% | 0.00% | 0.00% | 0.00% | 0.03 | 0.03 | -0.82 | -6.18 |
About BriaCell Therapeutics Corp.
BriaCell Therapeutics Corp. operates as a Phase 3 biotechnology company transforming cancer care with its novel cellular immunotherapies. It is conducting a pivotal Phase 3 clinical trial in advanced breast cancer with its Bria-IMT in combination with an immune check point inhibitor. It is also developing personalized off-the-shelf treatments for breast cancer, prostate cancer, and other cancers. The company has a collaboration with Incyte Corporation to evaluate combination of the Bria-IMT. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.
- CEO
- William V. Williams
- Employees
- 16
- Beta
- 2.03
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as (— ÷ —) − 1 = — (DCF, example).